Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
Divyanshu Dubey,1 Christopher A Cano,1 Olaf Stuve1–3 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology, Klinikum rechts der Isar...
Saved in:
Main Authors: | Dubey D, Cano CA, Stuve O |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/e848b4d154864ff8a42f4460ff32a5db |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
by: Babij R, et al.
Published: (2015) -
Disease-modifying therapies in relapsing–remitting multiple sclerosis
by: Fabricio González-Andrade, et al.
Published: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
by: Lugaresi A, et al.
Published: (2013) -
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
by: Mezei Z, et al.
Published: (2012) -
Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
by: Zhou F, et al.
Published: (2015)